Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer

類似資料

• Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer
  著者:: Feng, Haoran, 等
  出版事項: (2020)
• Potential Therapeutic Targets of B7 Family in Colorectal Cancer
  著者:: Wang, Changgang, 等
  出版事項: (2020)
• CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species
  著者:: Fu, Zhiping, 等
  出版事項: (2018)
• The role of E26 transformation-specific variant transcription factor 5 in colorectal cancer cell proliferation and cell cycle progression
  著者:: Peng, Yi, 等
  出版事項: (2021)
• Identification and validation of critical alternative splicing events and splicing factors in gastric cancer progression
  著者:: Feng, Haoran, 等
  出版事項: (2020)